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TrendyGenes, a computational 
pipeline for the detection 
of literature trends in academia 
and drug discovery
Guillermo Serrano Nájera 1, David Narganes Carlón 1,2,3 & Daniel J. Crowther 3*
Target identification and prioritisation are prominent first steps in modern drug discovery. 
Traditionally, individual scientists have used their expertise to manually interpret scientific literature 
and prioritise opportunities. However, increasing publication rates and the wider routine coverage 
of human genes by omic-scale research make it difficult to maintain meaningful overviews from 
which to identify promising new trends. Here we propose an automated yet flexible pipeline that 
identifies trends in the scientific corpus which align with the specific interests of a researcher and 
facilitate an initial prioritisation of opportunities. Using a procedure based on co-citation networks 
and machine learning, genes and diseases are first parsed from PubMed articles using a novel named 
entity recognition system together with publication date and supporting information. Then recurrent 
neural networks are trained to predict the publication dynamics of all human genes. For a user-defined 
therapeutic focus, genes generating more publications or citations are identified as high-interest 
targets. We also used topic detection routines to help understand why a gene is trendy and implement 
a system to propose the most prominent review articles for a potential target. This TrendyGenes 
pipeline detects emerging targets and pathways and provides a new way to explore the literature for 
individual researchers, pharmaceutical companies and funding agencies.
Pharmaceutical companies are actively looking for ways to reduce their attrition rates, the time taken for drug 
development, and the associated development  costs1–4. One approach being explored to address this productiv-
ity challenge is the exploitation of big biomedical data sets through machine  learning5,6. Evidence is emerging 
that machine learning can be used to speed-up and reduce the costs in all stages in drug  discovery5,6: drug 
 repurposing7,8, clinical  trials9,10, de-novo drug  design11–20, and target-disease  associations21–25. However, target 
identification and prioritisation remain the first step for the majority of drug discovery  programmes25–28. Only 
10% of drug targets progress through clinical  trials28–30 and this success rate appears lower for novel  targets30–32. 
Historically, target identification has been broadly carried out on a case-by-case basis, based on the scientific 
interpretation of the available literature. However, thousands of peer-reviewed articles are published every day 
without taking into account pre-prints, patent data, and clinical trial  reports33. PubMed alone contains more 
than 30 million publications as of 2020, and the scientific output doubles every nine  years34, creating a corpus of 
"undiscovered public knowledge"35. Thus, there is a high demand for machine learning and other computational 
methods to exploit the current knowledge and facilitate the maintenance of an overview of this overwhelming 
literature volume. The development of (i) alert systems to identify and rank emerging targets at genomic-scale 
and (ii) recommendation systems to prioritise detailed reading of scientific reviews is of importance for both 
pharmaceutical companies and the whole scientific  community25,27,36.
One of the most significant obstacles for the automatic analysis of biomedical literature is the use of non-
redundant alternative gene synonyms, symbols, and acronyms from competing sources that can have other 
meanings in different areas of  research37. Therefore, it is imperative to disambiguate biomedical entities in the 
scientific literature at the outset. There have been several attempts in this line of  research21–24,37–46. However, these 
attempts do not unambiguously map gene and disease entities in scientific literature to controlled ontologies 
nor do they define an ambiguity measure for gene and disease synonyms. Although there have been multiple 
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attempts about trend detection and burst term  detection48,49 and more concretely about the biomedical literature 
of targets and small  molecules50–52 to our knowledge this is the first attempt to analyse emerging trends about 
human protein coding genes.
Here we propose a new disambiguation algorithm based on co-citation networks and natural language pro-
cessing to obtain accurate publication dynamics for every coding-gene in the human genome. This time-series 
data was used to train recurrent neural networks (RNN) in historical data and predict the state of the literature 
in recent years. We identify which genes are being mentioned in the literature more than expected in order to 
highlight and rank potential targets. This genome scale ranking is not alone sufficient for target assessment 
since this will not include assessment of tractability, commercial opportunity or clinical translatability, but 
identification of emerging biology is a key component of novel target identification. When the actual number 
of published articles exceeds predictions, there may have been a paradigm shift for that particular gene. Finally, 
we implemented topic detection algorithms along with recommendation systems to validate trendy targets. 
Therefore, the aims of this paper are fourfold: (i) to unambiguously detect genes and diseases within articles 
with a novel named entity recogniser (ii) to generate a ranking of genes and diseases based on a novel metric 
that defines its trendiness, (iii) to generate an automatic pipeline to analyse why these biological entities may 
be trendy, and (iv) to generate a recommendation system to suggest which articles to read which maximise the 
information coverage in subnetworks.
Results
Gene annotation. We gathered the human gene synonyms from different sources (Ensembl, UniProt, 
HGCN, Entrez and OpenTargets; Fig. 1B) to sample the potential publications mentioning human gene names. 
Human genes had around 10 synonyms on average and many of those synonyms are ambiguous (Table 1): More 
than 30% of gene symbols had at least one promiscuous synonym, around 10% of the gene symbols are unsafe 
and have at least one gene synonym in the English dictionary, and almost 50% of gene symbols had a nested 
synonym. Combining these problems, almost 60% of the 19,082 gene symbols have one or more of these four 
types of ambiguity. To determine which synonyms are potentially ambiguous (“unsafe gene synonyms”; Fig. 1C) 
we did feature engineering to obtain variables that characterise unsafe synonyms (e.g. longer gene names are less 
probable to be ambiguous; Table 2). Next, we used a positive-unlabelled bagging (PU) strategy following Morde-
Figure 1.  Workflow. Chart summarising the process from the downloading of the data to the detection and 
analysis of trends in the literature. (A) Creation of a graph database with the information contained in PubMed 
baseline 2020. (B) Acquisition of a comprehensive collection of human coding gene names and synonyms. 
(C) Automatic determination of potential ambiguous (unsafe) gene names. (D) Annotation of the graph 
database with unambiguous gene symbols by combining co-citation network topology and binary classifiers. 
(E) Prediction of per-gene publication trends using RNN. When a gene has significantly more publications or 
citations than expected by the model it is considered to be trendy. (F) Automatic topic detection of collections 
of publications. We used this algorithm to quantify the evolution of topics in trendy gene publications over 
time. (G) A review recommender system that uses information from the citation network and topic detection to 
recommend the most efficient set of reviews to explore the literature.
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let et al.  implementation55 with a random forest classifier with the engineered features to calculate the probability 
of a gene synonym to be “unsafe” (see Methods).  
To link every human gene to a subset of publications we implemented a disambiguation pipeline based on 
co-citation networks and machine learning (Fig. 1D). We gathered the titles, abstracts and keywords of the 
publications that had a match for any of the synonyms using regex with ElasticSearch (Fig. 1D). Nevertheless, 
this original set of publications potentially contains false positives: publications that contain an ambiguous gene 
synonym in their titles or abstracts, that do not refer to the gene of interest.
We assumed that true and false positives synonyms will tend to belong to different communities of publi-
cations from different research fields. To detect these communities we used co-citation networks (Fig. 1D): a 
weighted graph where the weight of the edges represents the frequency of two publications being cited simul-
taneously (co-cited) by a third publication. When two publications are repeatedly co-cited it strongly suggests 
that both belong to the same field of  study56. We used the fast greedy modulation algorithm from iGraph to 
determine communities in the co-citation network and distinguished communities of publications focusing on 
the gene of interest by detecting the presence of “safe gene synonyms” in their titles and abstracts (Fig. 1D). The 
process is summarised in Fig. 2.
Finally, because we only used citations from open-access publications contained in PubMed Central (PMC)57, 
46% of the publications were disconnected in the PubMed co-citation graph. To tackle this problem, we used 
again the inductive bagging positive-unlabelled approach to train multiple classifiers to associate the discon-
nected publications with the previously computed co-citation network components (Fig. 1C) using the words, 
phrases and one to four n-grams, contained in titles and abstracts. All available machine classifiers in Scikit Learn 
were used but logistic regression was selected due to its speed to accuracy ratio (Table 3).
To test the performance of the disambiguation pipeline we compared the disambiguation results with the 
gene-publication annotations from  GeneRif58 (manually curated annotations),  DISEASES59 (computational 
annotations), and  UniProt60 (computational and manually curated annotations) (Table 4). On average, the dis-
ambiguation recovers > 85% of all publications contained in these databases. Both GeneRif and Uniprot annota-
tion do not necessarily contain a gene-synonym in the title or abstract, therefore those publications are out of 
our pipeline. Disambiguation results present on average a 70% precision with UniProt, the only collection of 
disambiguated publications of a similar magnitude. Finally, we included the disambiguated gene-publication 
annotations into the graph database.
Table 1.  Gene synonyms are ambiguous. Manually discarded synonyms were labelled as unsafe during 
the unsafe gene synonym detection in an active learning fashion (see Methods). Unsafe aggregates the data 
from all the other categories. Data for 19,082 gene symbols and 185,549 gene synonyms. The total counts 
represent the number of individual synonyms when grouped by gene symbol and gene synonym. Promiscuous 
synonyms are counted as many times as they act a synonym.




Manually discarded 58 0.03
Unsafe 24,491 13.20
Table 2.  Unsafe features. Engineered features to evaluate the probability of a given gene symbol of being 
ambiguous (unsafe).
Variable Meaning
Total Number of total PubMed ID candidates retrieved in ElasticSearch when querying for all gene synonyms for a given gene symbol
Contribution The percentage of PubMed IDs that a given gene synonym contributes to the total for a particu-lar gene symbol
Number of characters The length of the gene synonym in characters
Bits The sum of the bits of information of every character in a gene synonym based on the frequen-cies of each character in PubMed’s corpus of titles and abstracts
Number of nested The number of other gene synonyms that contain the gene synonym. For example: “Insulin” is part of “Insulin Receptor”
Prob. of the synonym given an alternative The conditional probability of finding the gene synonym given that an alternative synonym for the same gene symbol also appears in the text
Prob. of an alternative given the synonym The conditional probability of finding alternative gene synonyms given that the synonym synonym appears in the text
Is gene symbol Whether the synonym is also an accepted gene symbol
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Trend detection. To detect incoming trends in the literature we gathered the publication dynamics of a 
given human gene from the disambiguated graph database (Fig. 1E). These time series include the number of 
publications, clinical trials, reviews and publications from big and medium-sized pharmaceutical companies, 
as well as, citations of publications coming from the mentioned categories per calendar year. Specifically, if a 
manuscript with author affiliations to big pharma cites other publications these citations are categorized as big 
Figure 2.  Disambiguation pipeline. (A) Citation network for a subset of PubMed IDs mentioning any of the 
gene synonyms of the gene symbol LRWD1, including ORCA. (B) Co-citation network of the same subset of 
PubMed IDs as in (A). (C) Communities for the co-citation graph obtained after using iGraphs fast greedy 
algorithm: killer whale community, orca plant cluster, LRWD1 in drosophila and LRWD1 in heterochromatin. 
(D) Number of safe synonyms per PubMed ID in title or abstract in the same co-citation network. (E) Citation 
network with reviews citing any of the PubMed IDs. (E) Review information as defined by the recommender 
system scaled from 0 to 1.
Table 3.  Classifier comparison. Performance metrics for the 8 classifiers (Extra Trees Classifier, ETC; Gaussian 
Process Classifier, GPC; K-Nearest Neighbour, KNN; Logistic Regression, LOG; MultiLayer Perceptron 
Classifier, MLC; Ridge Classifier, RDC; Random Forest Classifier, RFC; and Support Vector Machine classifier, 
SVC; in descending order) used for the disambiguation in “Topic detection” for a random sample of 2000 
genes. The metrics shown in this table were obtained by averaging the results on the validation set during the 
threefold cross validation. Subsequently, the results were averaged for a sample of 2000 genes. The logistic 
regression classifier (bold) was the fastest and second most accurate model for a random sample of 2000 genes 
and therefore it was selected as the default model to run the disambiguation on the remaining 17,082 human 
protein-coding genes. This high validation score verified that there was no over-fitting after the threefold cross-
validation.
Classifier Accuracy Average precision Brier loss F1 Log loss Precision Recall AUC Time (s)
ETC 0.95 0.93 0.05 0.95 1.71 0.95 0.95 0.95 1.35
GPC 0.88 0.85 0.12 0.87 4.25 0.89 0.88 0.88 6.12
KNC 0.86 0.84 0.14 0.86 4.74 0.89 0.86 0.86 2.22
LOG 0.93 0.91 0.07 0.93 2.36 0.94 0.93 0.93 0.54
MLP 0.92 0.89 0.08 0.92 2.85 0.91 0.92 0.92 1.27
RDC 0.86 0.83 0.14 0.86 4.74 0.87 0.86 0.86 0.22
RFC 0.95 0.93 0.05 0.95 1.81 0.95 0.95 0.95 1.26
SVC 0.94 0.92 0.06 0.94 2.14 0.94 0.93 0.94 1.96
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pharma citations. Conversely publications citing this manuscript whose authors are affiliated to big pharma are 
not categorized as big pharma citations.
Time-series data from 1980 to 2013 was used to predict the per gene publication dynamics in each category 
between 2014 and 2019 using a Recurrent Neural Network model with an encoder-decoder architecture pre-
ceded by an attention layer, where both the encoder and decoder are composed of five hidden layers of Gated 
Recurrent Units (GRU). The time-series were created in a cumulative fashion, where each year contains the new 
publications and citations in addition to the previous ones.
For most genes, the model produces accurate predictions of the publication dynamics (Table 5), but for a 
small subset of genes the real number of publications or citations is significantly higher than expected (Fig. 3A). 
When the number of publications or citations exceeds the predictions, we interpret that the publication dynamics 
changed substantially in a way that cannot be explained simply by the gene’s publication history, implying that a 
meaningful discovery in the field has recently occurred (Fig. 3A; orange). Trendiness is defined as the probability 
of the fold-change between predicted and real number of publications and citations for a given gene. We used this 
metric to identify the trendiest genes in the academic community-using all publications-, or in the pharmaceuti-
cal industry-using publications coming from pharmaceutical companies-(Table S1, supplementary material). 
Finally, to identify trendy genes of pharmaceutical interest, we computed the normalised mutual information 
of genes and diseases in the titles and abstracts of publications (Fig. 3B). Disease names and their synonyms 
were obtained from the Medical Subject Headings (MeSH) ontology at the  Bioportal61. MeSH ontology contains 
4818 different disease nodes at different levels of the ontology. We created a dictionary for each disease with the 
preferred and alternative names (see Methods). The diseases were disambiguated in titles and abstract using the 
same disambiguation pipeline used with the genes.
We noticed that many trendy genes cluster forming trendy pathways when getting the gene–gene and gene-
disease association networks (Fig. 3C). We used enrichment of gene ontology (GO) terms for biological processes 
to uncover common pathways among the top 100 trendiest genes (Table S1, supplementary material). Among the 
most enriched GO terms in both academia and pharma are T cell co-stimulation, execution phase of necroptosis 
and pyroptosis. These biological processes are enriched in trendy genes which presumably reflect these fields of 
study are generating the most innovation and expectations in current biomedical research.
Topic detection. After the detection of gene trends, the next step was to understand why those genes might 
be trendy and curate possible mistakes in the disambiguation. With this aim we implemented a topic detection 
pipeline as an automatic, fast discovery tool to study groups of publications that mention the gene of interests 
(Fig. 1F). In this context, we used topic modelling algorithms. A topic is a collection of similar words, specific 
Table 4.  Comparison of disambiguation methods. Average recall and precision of the disambiguation of our 
disambiguation with other databases. Low precision values for DISEASES and GeneRIFs are due to the smaller 
size of these databases.
Recall Precision Total annotations
Uniprot 0.86 0.71 10,329,240
DISEASES 0.90 0.14 1,140,129
GeneRIF 0.86 0.11 726,532
Ours - - 9,658,406
Table 5.  Performance of the predictions. Performance in the predictions of the publication dynamics. The 
model predicts the publications dynamics per gene between 2014 to 2019 using data from 1980 to 2013. 
Numbers represent the median 13,380 human genes. MASE mean accuracy scaled error, RMSE root mean 
square error, Total number of elements in the database up to 2013.
Variables MASE Percentage of error RMSE Total (2013)
CIT. BIG PHARMA 0.42 12.51 10.60 1.86.E + 06
CIT. MED. PHARMA 0.50 14.90 5.20 6.59.E + 05
CIT. REVIEWS 0.30 3.35 45.60 2.38.E + 07
CIT. TRIALS 0.45 6.82 5.60 3.70.E + 06
CITATIONS 0.26 2.66 198.20 1.27.E + 08
PUB. BIG PHARMA 0.58 21.73 0.00 4.43.E + 05
PUB. MED. PHARMA 0.63 23.64 0.00 4.31.E + 05
PUBLICATIONS 0.33 8.66 32.60 9.48.E + 06
REVIEWS 0.52 13.37 2.40 9.07.E + 05
TRIALS 0.61 13.33 0.00 5.68.E + 05
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Figure 3.  Trend detection and gene–gene-disease co-occurrence. (A) Logarithmic scatter plots showing the 
predicted number of publications, reviews, citations and citations from big pharma companies against real data 
in the year 2018. (B) Trendiness (log2(predicted/real)) for genes associated with groups of diseases (MeSH 
parent categories). Left; Average trendiness of publications, reviews, citations and citations from reviews. Right; 
Average trendiness of citations coming from big and medium sized pharmaceutical companies. (C) Gene–
Gene–Disease co-occurrence network of the first neighbours of CD274. Orange nodes are diseases, grey nodes 
are genes and the size of gene nodes represents the trendiness The grey edges are gene-disease association, the 
blue edges are gene-diseases with the width of the edges reflecting the number of co-occurrences.
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to a group of  documents62. We used non-Negative Matrix Factorisation to generate a set of latent topics for each 
query (Fig. 4A; word clouds).
We explored the evolution of the topics associated with some trendiest genes. For the immune checkpoint 
inhibitors (CD274, PDCD1, TGIT and CTLA4) the topic timeline suggests that there was a rapid decrease in 
the likelihood of publications discussing the biological role of these immune checkpoint inhibitors since 2010 
(Fig. 4A in grey), which coincides with a notable increase in topics that discuss cancer therapies (Fig. 4A in 
orange) and monoclonal antibodies that target these four different transmembrane immunoglobulins (Fig. 4A in 
yellow).This way, the topic-detection pipeline is able to capture the evolution of the research from its biological 
description to the clinical application.
The topic timeline of the members of the necroptosis pathway (RIPK1, RIPK3 and MLKL; Fig. 4B) suggests 
that in the last decade there has been a decrease in the likelihood of publications discussing these genes in the 
context of apoptosis (Fig. 4B in grey), in favour of publications that discuss the newly discovered form of cell 
death, the necroptotic pathway (Fig. 4B in orange), as well as, the translational medicine perspective of this 
pathway as is suggested by words like mouse, treatment and activity or cancer (Fig. 4B, in blue).
Finally, the topic timeline the members of the pyroptosis pathway (CGAS, TMEM173, GSDMA and GSD-
MAD; Fig. 4C) shows a fast increase from 2013 of publications discussing the therapeutic opportunity in cancer 
immunotherapy with agonists for TMEM173 (Fig. 4B in grey), while again, the remaining topics seemed to 
contain information on the biochemistry and biological role of the genes.
Recommender system. In addition to the automatic topic detection, we designed a review recommender 
system to accelerate the screening of the publications that cover most of the information in a network (Fig. 1G). 
There are an average of 2.9 reviews citing any publication that mentions at least one gene name. The aim was to 
minimise the time reading and maximising the information within a gene subnetwork. The algorithm aggregates 
both topic and network information from the citation subgraph of the publications that mention the gene of 
interest to obtain the most query-centric reviews. The topic information comes from the latent topics obtained 
from the topic detection algorithm. The network information was captured by the PageRank scores of the sub-
graph (see Methods). This approach ensures that reviews citing publications with highest PageRank scores are 
prioritised. To further minimize the number of reviews for initial human analysis we avoid repetition of infor-
mation by simultaneously maximising the cumulative PageRank score whilst minimising the overlap of com-
bined citations. This way, we expect to obtain a small set of reviews that will cover the main topics and publica-
tions in the field. We used this recommender system to select the optimal subset of reviews to assess why genes 
might be trendy (see Discussion). An example of the output can be found for the genes in the discussion in the 
supplementary data file.
Discussion and conclusions
We present TrendyGenes as a first attempt to (i) establish a systematic analysis of contemporary topics associ-
ated to human genes and diseases, (ii) develop an alert system for emerging targets and trends in the scientific 
literature across the human, protein-coding genome, (iii) to use topic modelling to rapidly generate timelines of 
phrases that facilitate the understanding of why these genes are trendy.
We constructed a graph database containing PubMed data where publications are connected by citations and 
authors and are annotated with disambiguated human gene-names and diseases. We expect this new resource 
to provide new ways to navigate the scientific literature, detect and visualise networks of discussion and analyse 
networks of influence from key opinion leaders. Disambiguating author names from PubMed, MedRxiv, or 
BioRxiv would further improve the quality of the database. Machine or deep learning algorithms could be trained 
on already labelled data to improve on previously published  approaches63–65 and address this issue.
Similarly further improvements in gene-name disambiguation would assist precision and recall metrics on 
our validation set suffer for different reasons GeneRIF and DISEASES include fewer publications in comparison 
to the genome wide metrics identified in our pipeline and there will be a lot of potential “false positives”. This 
makes the precision of our approach appear lower than what it may actually be. On the other hand, GeneRIF and 
Uniprot contain publications which either are not gene specific or do not mention the gene in the title or abstract.
However, the disambiguated genes and diseases can serve as labelled data for more sophisticated deep learn-
ing approaches to annotate biomedical entities. Gene and disease entities could be better annotated using both 
representation learning to capture the network topology and contextual information with transformer layers. 
Topic detection could be improved by using the state-of-the-art text summarisers with deep learning.
The number of publications per gene in aggregate is very  predictable66. However, occasionally genes present 
significantly more publications than expected, meaning that a recent breakthrough occurred which cannot be 
accounted for from the publication dynamics. In this study, we show that trendiness can identify emerging targets 
from the literature for rapid profiling at genome-scale. We combined trendiness with gene-disease associations 
to prioritise potential drug targets: emergent genes associated with diseases but yet included in pharmaceutical 
publications are worthy of being investigated as potential targets. We observe that TrendyGenes usually cluster 
into the same biological pathways (Fig. 3C for CD274, PDCD1, CTLA4 and TIGIT). Here, using topic modelling 
and the recommendation system, we identify the trendiest genes and pathways and discuss some case studies to 
exemplify our pipeline. We selected genes pharmacological relevance by choosing genes with high trendiness 
both in the academia and the pharmaceutical industry with high association with disease and more than 100 
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Figure 4.  Topic time-lines. Topic time lines. Topic timelines for publications mentioning any of the genes for 
the immune checkpoint inhibitor (A), necroptosis (B) and pyroptosis (C) pathways. The x-axis represents the 
time in years and the y-axis represents the likelihood of a given topic. Colors represent different topics defined 
by the keywords contained in the correspondent word clouds. The latent four topics were obtained using Non-
Negative-Factorization all publications annotated with the genes after disambiguation. Word clouds were created 
using the phrases with highest TFIDF for groups of publications belonging to each topic. All timelines show at 
least one rising topic after 2013 that represents the reason why these genes became trendy, their implications in 
human disease: immune checkpoint inhibitors and monoclonal antibodies (yellow and orange in A), activation 
of necroptosis (orange in B), agonists of STING1 in cancer (black in C).
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Immune checkpoint inhibitors: CTLA4, CD274, PDCD1, TIGIT. CTLA4, PDCD1 (PD-1), CD274 
(PD-L1) and TIGIT are among the trendiest genes in academia and pharma in 2019 (Fig. 3A). CTLA4, PDCD1, 
CD274 and TIGIT genes encode four different transmembrane immunoglobulins that act as co-inhibitory 
receptors: checkpoints or ‘breaks’ for the adaptive immune response that prevent T cells from exerting their 
 functions67,68. CTLA4 competes with its analogous CD28 for CD80 and CD86 to prevent a premature activa-
tion of T  cells68. PDCD1-CD274 interaction counters the positive signals that may have already activated T 
effector  cells68. TIGIT interacts with CD155 to down-regulate natural killer cells and T  lymphocytes69. Can-
cer cells attempt to impair these checkpoints and currently there are 7 FDA approved monoclonal antibodies 
that target three of proteins (CTLA4:  Ipilimumab70; PDCD1:  Nivolumab71,  Pembrolizumab72,  Cemiplimab73; 
CD274:  Atezolizumab74,  Avelumab75) and multiple candidates targeting TIGIT (BGB-A121776, OMP-313M3277, 
 MTIG7192A78,  AB15479). Moreover, James Allison and Tasuku Honjo received the Nobel Prize in Medicine in 
2018 for its research on immune checkpoint  inhibitors47.
Neurodegeneration: TREM2 and C9orf72. C9orf72 encodes a guanine nucleotide exchange factor 
involved in endosomal trafficking and  autophagy80,81. Hexanucleotide repeat expansions in promoter or intronic 
regions of C9orf72 are some of the major causes of sporadic and familial forms of both amyotrophic lateral scle-
rosis and frontotemporal  dementia80. Antisense oligonucleotides are being used to impede the transcription of 
 C9orf7282–84 or CRISPR–Cas9 system to target the GGG GCC repeat in the  DNA85 or  RNA85,86.
TREM2 gene encodes a transmembrane immunoglobulin receptor expressed in macrophages, osteoclasts, 
dendritic cells, and brain  microglia87,88. TREM2 variants have been associated with Nasu-Hakola  disease89,90, 
late-onset Alzheimer’s  disease91–94, frontotemporal  dementia95–100, amyotrophic lateral  sclerosis101,102 and Par-
kinson’s  disease101,103. TREM2 activates a pathway—through TYROBP/DAP12—that promotes  inflammation87,88 
and promotes phagocytosis of cellular waste, remains of apoptotic cells, and  pathogens87,88. Currently, two inde-
pendent groups have generated anti-TREM2 antibodies to stimulate microglia to remove amyloid  plaques104. 
Furthermore, the mAb generated by one of these groups, Alenco, in collaboration with Abbvie, has entered 
Phase I clinical  trials105,106.
DNA sensing by cGAS–STING: cGAS, TMEM173, GSDMD, GSDMA. The cytosolic nucleic acid-
sensing pathway leads to pyroptosis, a lytic pro-inflammatory type of cell death involved in antiviral, antibacte-
rial, and anticancer  response107. cGAS is a nucleotidyl-transferase that catalyzes production of cyclic GMP-AMP 
(cGAMP) upon the recognition of double-stranded  DNA107. TMEM173 (STING) binds to cGAMP and pro-
motes the activation of both TBK1 and IRF3, increasing the transcription of genes encoding type I  interferons107. 
GSDMA and GSDMD are pore-forming effector proteins in the plasma membrane to release proinflammatory 
interleukins like IL-1β and IL-18108. The cGAS-STING pathway has been associated to multiple autoimmune and 
chronic inflammatory diseases like non-alcoholic fatty liver  disease109, systemic lupus  erythematosus110, vascu-
lar and pulmonary  syndrome111, macular  degeneration112, Bloom  syndrome113, Aicardi-Goutières  syndrome114, 
 cancer115, DNA  damage116,  neurodegeneration117 and beyond. Currently, there are ongoing clinical trials for 
 TMEM173118–120 and  GSDMD121 although there are no reported trials for GSDMA nor cGAS.
Necroptosis: RIPK1, RIPK3, and MLKL. RIPK1, RIPK3 and MLKL form part of the tumour necrosis 
factor-induced necroptosis  pathway122–124. This pathway has been associated with multiple pathologies: systemic 
inflammatory response  syndrome125,126, ulcerative  colitis127,128,  psoriasis128, rheumatoid  arthritis128, neurodegen-
erative  diseases129 and even  cancer130–132. TNFR1, FasL, TRAIL, and TLR can all activate RIPK1 to decide the 
cell’s fate: inflammation, apoptosis or  necrosis133. If caspase-8 is inhibited, RIPK1 and RIPK3 form the necro-
some that subsequently phosphorylates  MLKL134. MLKL forms homo-trimers135,136, migrates to the plasma 
 membrane135,136, binds to highly phosphorylated inositol  phosphates137, creates pores in the  membrane138 and 
disrupts the cell integrity. The discovery of RIPK1 dates back to  1995139. Since then, four inhibitor programs have 
progressed through human phase II safety  trials140–143. The first publication mentioning MLKL is more  recent144 
and, despite the lack of kinase activity, pharmaceutical companies have cited its publications by 60 times more 
since 2013. Although there are no clinical trials yet, there are at least three known different chemical  inhibitors145.
Mechanobiology: YAP1/WWTR1, PIEZO1 and PIEZO2. Cells use mechanical cues from their envi-
ronment to guide behaviours such as proliferation and migration. Forces act as signals which are transduced to 
the nucleus where they control gene  expression146. Mechanical forces are critical regulators of organ and tissue 
homeostasis, morphogenesis and regeneration, and are important aspects of diseases like cancer, metastasis, fibro-
sis and cardiac hypertrophy. YAP1/WWTR1 (TAZ) are transcriptional co-activators and  mechanotransducers147. 
YAP/TAZ is hyperactivated in  cancers148, its inhibition reduces  atherogenesis149 and  fibrosis150, it triggers pul-
monary  hypertension151 , and it is necessary for epithelial regeneration in the  intestine152. PIEZO1 and PIEZO2 
are two mechano-sensitive cation channels that play a key role in cell number  regulation153,154 and  migration155, 
 hearing156,  neural157 and  vascular158 development, somatosensory  functions159,  proprioception160 and beyond. 
Piezo channels have been recently associated with multiple pathologies like  arthrogryposis161,  apnea162, con-
genital lymphatic  dysplasia163,  hyperalgesia164,165,  malaria166,  pancreatitis167,  xerocytosis168, Gordon syndrome, 
Marden-Walker Syndrome, and Distal Arthrogryposis Type  5169. The discovery of mechanotransduction signal-
ling pathways has received notable attention in the last years and may open the door to new therapeutic strate-
gies to treat these  diseases147.
Trends in scientific literature are useful for pharmaceutical and biomedical companies. Moreover, this 
approach can offer crucial information to funding agencies to prioritise projects and a new way to study the 
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research impact. Finally, individual researchers may benefit from a new methodology to explore the literature 
and from algorithms to maximise the efficiency of navigating over an increasingly vast biomedical literature.
Material and methods
Terminology. Here we use the term gene symbol to mean the approved symbol for any of the 19,084 human, 
protein-coding genes accepted by the HUGO Gene Nomenclature Committee. We refer to gene synonyms as 
any of the possible gene name variations by which the scientific community has ever referred to a given gene. 
Approved gene symbols are also included in the gene synonyms. For example: ‘EGFR’ is the approved gene sym-
bol whereas ‘EGFR’, ‘Epidermal Growth Factor Receptor’, ‘ERBB1’, ‘ErbB-1’, ‘c-erbB1’, ‘HER1’, ‘ERBB’ are gene 
synonyms. We define promiscuous gene names as any gene synonym that is a synonym of more than one gene. 
This can include previous official gene symbols since these will not have been expunged from the literature. An 
example of this could be ‘ARP1’ which is a promiscuous gene synonym for the gene symbols ‘NR2F2’, ‘ACTR1A’, 
‘ACTR1B’, ‘ANGPTL1’, ‘APOBEC2’, ‘ARFRP1’, ‘PITX2’47. Unsafe gene synonyms are gene synonyms that may 
have a different meaning in other areas of research or in another context, for instance in standard English. The 
‘STAR’ gene symbol is unsafe as opposed to its gene synonym ‘Steroidogenic Acute Regulatory Protein’ or CCP4 
is both a gene synonym and the name for crystallography software. The final type of synonym we distinguish are 
Nested gene synonyms. These are gene synonyms that are part of another gene synonym. For instance ‘insulin’ is 
a nested gene synonym of ‘insulin receptor’, ‘TNF’ is nested gene synonym of ‘TNF Receptor Superfamily Mem-
ber 1A’ (gene symbol ‘TNFRSF1A’) and ‘TNF Receptor Associated Factor 2’ (gene symbol ‘TRAF2’).
Pubmed as a graph database. PubMed baseline  202053 comprises 30,419,056 publications for biomedi-
cal literature from MEDLINE and life science journals and 173,572,773 citations from the full-text archive of 
open-source publications PubMed Central (PMC). PubMed was imported into a graph database (Fig. 1A) for 
a fast performance in the retrieval of highly relational data like authorship and citation networks. In a graph 
database information is represented as nodes and edges, allowing the fast retrieval of queries about relation-
ships. We loaded PubMed 2020 base-line into  Neo4J54, an open source graph-database management system. 
We introduced four node types (publications, authors, human protein-coding genes, human diseases, medi-
cal subheadings), and four edge types (published, from authors to publications; cited by between publications, 
gene annotation from genes to publications; and disease annotation from diseases to publications). Furthermore, 
PUBLICATION nodes have the following attributes: PubMed identifier, title, abstract, affiliations, is_review, 
is_clinical_trial, big_pharma, med_pharma and date of publication. Profiling of the graph is included in Table 6, 
Database Profiling. Neo4J offers an interactive approach to navigate through PubMed (i) easily accessing refer-
ences of publications, (ii) with the ability to query for specific genes and diseases already disambiguated, and (iii) 
with the aim of creating a knowledge graph for further exploration of gene-disease associations. The database 
is accessible to download at: https:// mega. nz/ file/ 4E8Qj CaQ# oqtm7 jof- lsG7y Sget8 uakh7 m26bD Lo1Hr Pu3mt 
dAV8.
Gold standard sets. GeneRif58, UniProt, and  DISEASES59 were used as a golden-standard for validation.
Pharmaceutical companies. A list of organisation names was generated from  Cortellis170. Organisations 
with more than 100 patents in Cortellis were considered ‘big pharma’ and ‘mid pharma’ otherwise.
Table 6.  Database profiling. We loaded PubMed 2019 base-line into Neo4J, an open source graph-database 
management system. We introduced four node types (PUBLICATION, AUTHOR, GENE, DISEASE), and 
four edge types (PUBLISHED, from AUTHOR to PUBLICATION; CITED_BY between PUBLICATION, 
GENE_PMID_ASSOCIATION from GENE to PUBLICATION; and DISEASE_PMID_ASSOCIATION from 
DISEASE to PUBLICATION). Furthermore, PUBLICATION nodes have the following attributes: PMID, 
TITLE, ABSTRACT, AFFILIATIONS, IS_REVIEW, IS_CLINICAL_TRIAL, BIG_PHARMA, MEDIUM_
PHARMA and DATE. The database is accessible at: https:// mega. nz/ file/ 4E8Qj CaQ# oqtm7 jof- lsG7y Sget8 
uakh7 m26bD Lo1Hr Pu3mt dAV8.
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Gene annotation. Search for publications. A ElasticSearch API search engine was used to retrieve Pub-
Med IDs of publications containing a gene or disease synonym in their title, abstract or keywords (Fig. 1D; GET 
PMIDs and GET corpus). These PubMed IDs were later used to retrieve the publications’ attributes from Neo4J 
using Cypher language through its python  driver171 (Fig. 1E; GET trends). Regular expressions were used avoid 
nested name ambiguity with lookarounds and fuzzy matching to account for case and punctuation and letter 
case variations (e.g. ‘ErbB-1’, ‘erbB1’, ‘ERBB1’, ‘ErbB 1’).
Unsafe synonym detection. We used 19,082 protein-coding human genes annotated by HUGO Gene Nomen-
clature Committee (HGNC). Gene synonyms were obtained from Ensembl, HUGO, Entrez, UniProt and Open 
Targets (Fig. 1C). Gene synonyms which were identical to disease names contained in the Medical Subject Head-
ings (MeSH) database were eliminated. This mainly occurs when genes are named after diseases that are associ-
ated with e.g. ‘Li Fraumeni syndrome’ as a gene synonym for gene  TP53172 or ‘Marfan syndrome’ in ‘FBN1’173.
Gene synonyms were classified into “safe” or “unsafe” categories using a modified version of the positive-
unlabelled learning with bootstrap-aggregating as implemented by Mordelet et Vert (PU-learning; Fig. 1C)55. PU 
learning is a form of semi-supervised learning which iteratively finds positive examples within a-priori unlabeled 
data. To build a binary classifier able to distinguish the unlabelled class (U) into unsafe (P, positive) and safe (N, 
Negative) we engineered a series of features (Table 2, Unsafe features) such as the combined frequency of the 
characters in a gene synonym (example: ‘ZNF’ will be safer than ‘EDA’ because ‘Z’ and ‘F’ characters are less fre-
quent in PubMed corpus than ‘E’, ‘D’, and ‘A’) or the probability of a gene synonym given that other gene synonym 
appeared in the text (the probability of ‘STAR’ given ‘Steroidogenic Acute Regulatory Protein’ is high but the 
probability of ‘Steroidogenic Acute Regulatory Protein’ given ‘STAR’ is low because ‘STAR’ is more ambiguous).
The PU learning was run for five iterations with a random forest classifier. The pure positive class (unsafe) 
was constructed combining gene synonyms present in the Enchant English  dictionary174, gene synonyms with 
less than three characters, and promiscuous gene synonyms. In an active learning fashion, after each iteration, 
the top 1000 examples with the highest probability of being unsafe were manually relabelled if they were wrongly 
classified. For example, true positive unsafe synonyms like gene families (e.g. ‘G protein coupled receptor’), phe-
notypes (e.g. ‘Williams Beuren Syndrome’) and other biological entities (e.g. ‘Cell surface antigen’) were included 
in the true positive set for the next iteration. False positives like ‘thymopoietin’ or ‘tubulin alpha-1C chain’ were 
included into a new true negative class for the remaining iterations.
After the five iterations, a gene synonym was considered unsafe if: (i) it is included in the English dictionary 
from Enchant, (ii) it is a word with less than three characters, (iii) if the predicted score for the random forest 
classifier was higher than 0.5, and (iv) it is a promiscuous gene synonym .
Community detection. We produced weighted, undirected co-citation networks from unweighted, directed 
citation networks (Fig. 1D, GET communities). Subsequently, connected components were broken into com-
munities using the fast greedy modulation algorithm implementation in  iGraph175.
Gene annotation. Communities in co-citation networks represent different areas in the scientific literature. We 
used this feature to disambiguate large groups of publications (Fig. 1D, LABEL communities). We labelled all the 
publications in a community with the gene symbol of interest if the ratio of publications mentioning at least one 
safe synonym with respect of publications that only mention unsafe synonyms was higher than 0.1%.
Nevertheless, the co-citation graph is incomplete because PMC only contains citations of open-source pub-
lications. Because of that, 46% of the publications were disconnected from the co-citation graph. Disconnected 
publications that mention a safe-synonym were automatically linked to the gene symbol of interest. The rest 
of disconnected publications were linked to gene of interest using PU bagging  strategy55 with a binary logistic 
regression classifier based on the words in the text corpus (keywords, titles and abstracts) of communities already 
linked to the gene of interest and discarded communities.
Each corpus was pre-processed by (i) removal of non-alphanumeric characters, (ii) tokenization or split by 
whitespace, (iii) deletion of stop words from  NLTK176, (iv) lower case conversion, (v) deletion of tokens whose 
length is less than three characters, (vi) deletion of token representing integers and (vii) stemming (‘disambigu-
ated’, ‘disambiguations’, ‘disambiguating’ is converted to ‘disambiguat’). List of tokens (uni-, bi-, tri-, tetra-grams) 
with at least 2 counts and a frequency lower than 0.6 in the complete corpus were vectorised using TF  IDF177. 
When there were less than 1000 unlabeled publications in the training set for the gene of interest, we generated 
an auxiliary negative class to augment the negative examples in the training data. This auxiliary negative class 
comprised a random sample of 1000 publications that mentioned genes different from the gene of interest.
These vectors were fed to all available machine learning classifiers from the Python library sklearn: Extra Tree 
Classifier, Gaussian Process Classifier, K-Nearest Neighbour, Logistic Regression, Ridge Classifier, Random Forest 
Classifier, and Support Vector Machine. All classifiers were trained with hyper-parameter tuning and threefold 
cross-validation to avoid over-fitting in each of the 50 PU-bagging iterations (Table 7). The implementation of 
this PU learning algorithm is the same as the inductive bagging positive-unlabelled learning with bootstrap-
aggregating approach described by  Mordelet55 (PU-learning; Fig. 1D) and also the same as in the section of 
“Unsafe Synonym Detection” of the Methods (PU-learning; Fig. 1C). To maximise specificity and sensitivity 
simultaneously we selected the models with highest weighted F1 score (Scikit Learn) to maximise precision 
and recall at the same time. We selected the logistic regression (LOG, Table 3) classifier for the disambiguation 
pipeline given its accuracy-speed balance (Table 3).
Disease annotation. The same procedure used for gene entity recognition was used to detect disease enti-
ties, co-citation networks and machine learning. The Medical Subject Headings (MeSH) ontology was down-
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Table 7.  Hyper-parameters for model selection. Hyper-parameters used during the model selection for 
Table 3. ClassifierName column contains the name of the classifier and our acronym. Some classifiers were 
grouped since they have similar hyper-parameters like ExtraTreesClassifier (ETC) and Random Forest 
Classifier (RFC); and RidgeClassifier (RDC) and LogisticRegression (LOG). HParamName contains the names 
of the hyper-parameter names in the same format as sklearn version 0.24.2 (stable). ValuesToUse column 
contains the list of potential values of those hyper-parameters to be evaluated. Some values are specific for only 
one classifier and therefore have the acronym for the model in parenthesis (e.g. ‘lsqr’ (RDC) and ‘lbfgs’ (LOG)). 
random_state and class_weight hyper-parameters were intended to have the same value across all models. The 
validation_fraction was used in MLPC to use the feature of early stopping : this created a sub-validation set 
under the training set different from the validation sets created for the cross-validation.
ClassifierName HParamName ValuesToUse




max_depth [10, 20, 30]
max_features [“auto”, “sqrt”, “log2”, 0.5]
max_samples [None, 0.6]
min_impurity_decrease [1e−5, 1e−4, 1e−3]










leaf_size [10, 20, 30, 40, 50]
metric ["euclidean","minkowski","mahalanobis","chebyshev"]




















solver [‘lsqr’ (RDG), ‘sparse_cg’ (RDC), ‘sag’, ‘saga’, ‘lbfgs’ (LOG), ‘liblinear’(LOG), ‘newton-cg’(LOG)]




C [0.1, 1, 10]
degree [1, 2, 3, 4]
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loaded by querying their Rest-API available at  BioOntology178. We constructed a key-value dictionary. Each dis-
ease was a node in the ontology. The disease synonyms were obtained from the ’Concept List Terms’ field in the 
ontology to gather the preferred and the alternative ways of denoting the disease. We generated more synonyms 
of the diseases by reversing the order of synonyms with commas: ’Insipidus, Diabetes’ to ’Diabetes Insipidus’.
Gene–gene-disease co-occurrence. Co-occurrence. Co-occurrence of genes and diseases was com-
puted using the simultaneous occurrence of gene/disease tags in publications after disambiguation, normalized 
by the total number of publications presenting those tags. We also computed mutual information metrics for 
gene–gene and gene-disease associations.
Gene mesh-parent association. Every disease MeSH term was associated with its lowest ancestor in the MeSH 
ontology under the node  Disease179. After computing the gene-disease co-occurrence, each gene is linked with 
the most frequent ancestor disease term (Fig. 3B).
TrendyGenes. Trendiness. In this paper the trendiness for a gene is defined as the probability of observing 
the magnitude of fold-change between the predicted and the real number of publications for that given gene. The 
error in the predictions is inevitably higher with genes associated with small numbers of publications. To correct 
for this, we generated five bins based on the initial number of publications (percentiles 20, 40, 60, 80 and 100). 
We computed the distribution of the fold-changes between the predictions and observed reality in each of the 
five bins using a gaussian kernel density estimator available at Scikit Learn (bandwidth = 0.1, remaining param-
eters with default values). The area under the obtained probability density function is equal to 1. Trendiness is 
the area of the right tail of the probability density function bounded to the left by the observed fold change. This 
gives us an estimate of how extreme the fold change was for that gene in a specific bin.
RNN model. The model consists of an encoder-decoder architecture preceded by an attention layer. Both the 
encoder and decoder were composed of five hidden layers of Gated Recurrent Units (GRU). The model was 
implemented in Keras using the Tensorflow-GPU backend. Min–max normalization was used to rescale the 
time series before training. The optimizer was RMSprop and the loss was computed as the log error. 30 percent 
of the time series was reserved for validation during the training.
Model optimisation. Input data was in both forms: cumulative and differential. In the cumulative model each 
year contains all the publication and citations published until then, while the differential model only contains 
the publications published in that year. Multiple normalisations were used (’none’, ‘minmax’, ‘log’, ‘standard’, and 
combinations of them). Similar results were obtained with different normalisations and minmax was finally 
selected. Multiple Recurrent Neural Networks (RNNs) architectures were used (GRU, LSTM) in the form of 
encoder-decoder, with different numbers of neurons (1, 5, 10, 20, 50; Table 8). Models were compared with 
the Mean Accuracy Scaled Error (MASE), an unbiased method to compare time-series prediction models by 
comparing how much each model out-performs a naive model that repeats the last value. The 5-neuron-GRU 
with cumulative time-series was selected because it was the most parsimonious model with the smallest MASE.
Gene ontology terms enrichment. For the enrichment of gene ontology terms (Biological Process) associated 
with the 100 trendiest genes in academia (all publications) and the pharmaceutical industry we used the online 
tool GeneCodis 4.0180 with default parameters.
Recommender system. Topic detection. We implemented algorithms to detect topics in collections of 
publications. This is useful to determine in which areas trendy genes are relevant. Furthermore, topic detection 
Table 8.  Model size comparison. Global performance of the RNN model. Mean accuracy scaled error (MASE) 
is an unbiased method to compare time-series prediction models by comparing how much each model out-
performs a naive model that repeats the last value. Values below 0 indicate that the method performs better 
than the naive model. Data for 13,380 human genes.
Variables
Median MASE
1 GRU 5 GRU 10 GRU 20 GRU 50 GRU 
CIT. BIG PHARMA 0.46 0.42 0.42 0.41 0.42
CIT. MED. PHARMA 0.51 0.50 0.47 0.48 0.48
CIT. REVIEWS 0.38 0.30 0.25 0.24 0.26
CIT. TRIALS 0.45 0.45 0.43 0.43 0.43
CITATIONS 0.39 0.26 0.21 0.23 0.25
PUB. BIG PHARMA 0.66 0.58 0.56 0.54 0.55
PUB. MED. PHARMA 0.76 0.63 0.56 0.55 0.55
PUBLICATIONS 0.48 0.33 0.26 0.26 0.26
REVIEWS 0.53 0.52 0.50 0.46 0.50
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allows the fast identification of errors during the disambiguation. We used two different topic detection algo-
rithms: Latent Dirichlet  Allocation62 (LDA), and Non-Negative Matrix  Factorisation181 (NMF). Both algorithms 
factor a nonnegative matrix ‘A’ with size NxM, where N is the number of publications and M is the dimension 
of the TF IDF vector obtained for Named Entity Recognition (see above), into non-negative factors matrix W of 
size NxK and matrix H with size KxM where WxH is an approximation of matrix A. The matrix W contains the 
strength of the association of a given publication to belong to a latent topic while H contains the strength of the 
association between a latent topic and a given n-gram. Scikit Learn implementations for both algorithms were 
used to generate ’K’ number of topics defined by the user with the default parameters until convergence (toler-
ance of 1e−12). We previously used  perplexity182 to select the optimal number of topics but we disagreed with 
the output: the number of topics that model the corpus better was not necessarily the most human interpretable. 
Topic timelines were obtained by calculating the mean and standard deviations of the topic probabilities for all 
publications mentioning the gene of interest per calendar year (Fig. 4).
Recommendation algorithm. We implemented an automatic pipeline to guide users about which reviews to 
read for a specific query in PubMed. To do that, we used the topic probability of the publications and an aggre-
gated PageRank score of the citation networks. The user can select an interval number of reviews (R) that is will-
ing to read: between 2–3 or 3–50. Then, three matrices are defined for each group of publications: (i) a binary, 
sparse matrix of size NxR with N publications and R reviews that comprised the citation adjacency network; (ii) 
a Nx1 weight matrix that comprise a PageRank scores; and (iii) a NxK matrix with the topic probabilities for N 
publications and K user-defined topics.
The score for each review was defined as the sum of the PageRank scores of its references while the score for 
a combination of reviews is defined as the row sum of the indexed NxR matrix multiplied by the Nx1 PageRank 
vector and the sum of the obtained vector. Results were later normalized by the total maximum score, defined 
as a hypothetical review citing all gene publications. Finally, every combination of R reviews is presented to 
the user with the score, the average of the cited publication dates and the probability to belong to one of the K 
previously defined topics.
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